Whalesbook
New Oral GLP-1 Drugs Poised to Enter India by 2026
India's obesity treatment market is set for a major change by late 2026, as numerous oral GLP-1 drugs prepare to enter. Experts and doctors expect this to significantly alter the market, driven by new oral treatments that offer easier access and potentially lower prices than existing injectable options. Eli Lilly is progressing its non-peptide oral GLP-1, orforglipron (Foundayo), with filings expected soon and possible approval in late 2026. Meanwhile, Structure Therapeutics plans to start its Phase 3 trials for aleniglipron by mid-2026, following positive Phase 2 results showing substantial weight loss.
Chinese Firms Drive Innovation and Lower Costs
Chinese biotech companies are key players, developing almost a dozen oral GLP-1 drugs. Many of these are non-peptide small molecules, meaning lower manufacturing costs. This could lead to more affordable options for Indian patients, who strongly prefer pills. Indian drugmakers are also stepping up, such as Lupin partnering with Gan & Lee Pharmaceuticals for Bofanglutide, a bi-weekly injectable GLP-1. While not an oral drug, this partnership shows the strategic focus on the GLP-1 market and the potential for local development.
Price Wars Loom as Generics Emerge; Efficacy Key to Winning
While new drugs offer easier access, the market faces intense competition and falling prices. The patent expiry of semaglutide in India in March 2026 has already led to quick launches of generic versions by 13 companies. This has increased competition and is pushing prices down for established brands from Novo Nordisk and Eli Lilly. The situation indicates that while pills are convenient, the drugs that succeed long-term will be those showing better effectiveness and lasting affordability. Eli Lilly's Mounjaro has seen its market share decline despite strong sales, partly due to generic rivals. The market for GLP-1 drugs in India was worth about USD 110-115 million in 2024 and is expected to grow rapidly to USD 1.9-3.4 billion by 2032.
Key Companies, Market Growth, and Financials
Major global companies like Eli Lilly (with a market value estimated in the hundreds of billions of USD and a P/E ratio around 39x) and Novo Nordisk are significant players. Innovent Biologics, a key Chinese firm, has a market capitalization of $20.1 billion as of April 2026. Gan & Lee Pharmaceuticals, also Chinese, has a market cap of about $4.7 billion and a P/E of roughly 41.60. Lupin, a major Indian company, is actively growing its diabetes and obesity offerings via partnerships. The Indian market is forecast to grow at a compound annual rate (CAGR) of 34.3% from 2025 to 2030, showing significant growth potential, though rapid saturation and pricing pressures pose risks. Ascletis Pharma, trading around HK$17.61, is also developing oral GLP-1 drugs.
Challenges Remain: Cost, Efficacy, and Competition
The convenience of pills is a major plus, meeting a key need in a healthcare system where over 75% of patients prefer oral medications. However, the long-term effectiveness and safety of these new drugs will face scrutiny. The high cost of these GLP-1 treatments remains a barrier for many Indians. Additionally, drug approval processes can be long, potentially delaying launches. Competition is growing not just from new drug entries, but also from non-drug approaches and other diabetes medications like SGLT-2 and DPP-4 inhibitors. These could offer cost advantages if their weight-loss results are similar. Ultimately, the success of these new oral GLP-1s will hinge on their ability to provide a strong offering that balances effectiveness, safety, and price amid fierce competition and changing patient needs.